Product Information
ZITUVIMET XR 50-1,000 MG TABLET is a brand product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $5.0193 per EA under NDC 70710180506. Its NADAC has been published 76 times since Apr 23, 2025.
FDA first approved this application on Jul 18, 2024.
Strength
1000; 50 mg/1; mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710180506
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METFORMIN HYDROCHLORIDE; SITAGLIPTINApproval Type
New Drug (NDA)
FDA Application
NDA216778FDA Approved
7/18/2024
On Market Since
10/31/2024
Pharmacological Classes
Price Statistics
The NADAC for ZITUVIMET XR 50-1,000 MG TABLET has been published 76 times since Apr 23, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.0193 per EA |
|---|---|
| All-time high | $5.0613 (May 14, 2025) |
| All-time low | $5.0193 (Sep 23, 2026) |
| 52-week high | $5.0404 |
| 52-week low | $5.0193 |
| Median price | $5.0348 |
| Average price | $5.0361 |
| Largest weekly change | -0.1% (Jul 23, 2025) |
| Weeks tracked | 76 |
| Tracking since | Apr 23, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sitagliptin and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZITUVIMET XR 50-1,000 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ZITUVIMET XR 50-1,000 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $5.0193 per EA (NDC 70710180506), effective Sep 30, 2026.
How has the price of ZITUVIMET XR 50-1,000 MG TABLET changed over time?
Over the history we have for it, the NADAC for ZITUVIMET XR 50-1,000 MG TABLET has held within roughly two percent of its current level. It has been tracked across 76 weekly CMS publications since Apr 23, 2025.
What are the highest and lowest recorded NADAC prices for ZITUVIMET XR 50-1,000 MG TABLET?
Since Apr 23, 2025, the NADAC for ZITUVIMET XR 50-1,000 MG TABLET has ranged from a low of $5.0193 (Sep 23, 2026) to a high of $5.0613 (May 14, 2025), with a median of $5.0348 per EA.
Are there cheaper alternatives to ZITUVIMET XR 50-1,000 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ZITUVIMET XR 50-1,000 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ZITUVIMET XR 50-1,000 MG TABLET?
ZITUVIMET XR 50-1,000 MG TABLET (NDC 70710180506) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a brand product.